Anthropic Ships an AI Workbench for Life Sciences — And Names the Trust Gap Holding Adoption Back

Novo Nordisk, the Garvan Institute, and Benchling are the first named customers for Claude Science, Anthropic’s new beta AI workbench for life-sciences research, published this week as a product guide. The pitch is narrow and specific: let scientists run analysis, generate figures, and produce reproducible results while keeping data and compute on their own infrastructure, deployed across three surfaces — Claude Science for analysis, Claude Cowork and Claude for Microsoft 365 for documentation, and Claude Code for production pipelines — with a three-phase Foundation/Pilot/Scale adoption roadmap.

The numbers Anthropic cites frame exactly why that roadmap needs to be deliberate: 78% of biopharma and medtech leaders expect AI to drive major change in their organization this year, but only 14% report full AI implementation in daily workflows. Separately, 91% of surveyed scientists say they want more AI in their research, while 79% cite trust and reliability as the primary barrier — a gap between appetite and confidence, not appetite and interest.

That specific trust-versus-appetite framing echoes what Outreach’s own governance research found across enterprise AI broadly: Deloitte data showing only 11% of organizations have agentic AI running in production despite 38% piloting it, even as IDC projects 40% of Global 2000 roles will directly engage an AI agent by year-end. Both findings point to the same mechanism — pilots move fast, production deployment stalls on governance and trust, not on capability. Claude Science’s answer is auditability: Anthropic frames it as producing results that “can be traced, reproduced, and defended,” a phrase aimed less at scientists than at the compliance reviewers standing between a pilot and a production rollout in a regulated, high-stakes domain.